Patients with end-stage liver disease (ESLD) have a poor quality of life, which often worsens as disease severity increases. Palliative care (PC) has emerged as a management option in ESLD patients, especially for those who are not candidates for a liver transplant.
Objective:
To assess the associated factors and trends in PC utilization in recent years.
Design:
We used the 2016–2020 National Inpatient Sample (NIS) database of the United States to identify patients with decompensated cirrhosis who suffered in-hospital mortality. Information regarding patient demographics, hospital characteristics, etiology and decompensations, Elixhauser comorbidities, and interventions was collected. The multivariate regression model was used to identify factors associated with PC use.
Results:
Out of 98,160 patients, 52,645 patients (53.6%) received PC consultations. PC utilization increased from 49.11% in 2016 to 56.85% in 2019, with a slight decrease to 54.47% in 2020. Patients with PC use had decreased incidence of blood transfusions (28.85% vs. 36.53%, p < 0.001), endoscopy (18% vs. 20.26%, p 0.0001), liver transplantation (0.28% vs. 0.69%, p < 0.001), and mechanical ventilation (46.22% vs. 56.37%, p < 0.001). African American, Hispanic, and Asian/Pacific Islander patients had 29%, 27%, and 23% lower odds of receiving PC than White patients. Patients in the two lowest income quartiles had 12% and 22% lower odds of receiving PC compared with the highest quartile.
Conclusions:
PC utilization in patients with ESLD is associated with decreased invasive procedures, shorter lengths of stay, and lower hospitalization charges. Minorities, as well as patients in the lower income quartiles, were less likely to receive PC.
Get full access to this article
View all access options for this article.
References
1.
AsraniSK, DevarbhaviH, EatonJ, et al.Burden of liver diseases in the world. J Hepatol, 2019; 70(1):151–171; doi: 10.1016/j.jhep.2018.09.014
2.
VillarroelMA, BlackwellDL, JenA. Tables of Summary Health Statistics for U.S. Adults: 2018 National Health Interview Survey. National Center for Health Statistics. Source: NCHS, National Health Interview Survey,, 2018; 2019. Available from: https://www.cdc.gov/nchs/nhis/SHS/tables.htm [Last accessed: July 2023].
3.
MokdadAA, LopezAD, ShahrazS, et al.Liver cirrhosis mortality in 187 countries between 1980 and 2010: A systematic analysis. BMC Med, 2014; 12:145; doi: 10.1186/s12916-014-0145-y
4.
KimD, CholankerilG, LiAA, et al.Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005–2014. Liver Int, 2019; 39(9):1661–1671; doi: 10.1111/liv.14135
5.
EverhartJE. Ch. 21: Liver Disease. In: The Burden of Digestive Diseases in the United States. (Everhart JE. ed.). US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Washington, DC. US Government Printing Office, NIH Publication No. 09-6443; 2008; pp. 111–114.
6.
PeeryAF, CrockettSD, MurphyCC, et al.Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2021. Gastroenterology, 2022; 162(2):621–644; doi: 10.1053/j.gastro.2021.10.017
7.
DasK, DasK, DattaS, et al.Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis. Liver Int, 2010; 30(7):1033–1042; doi: 10.1111/j.1478-3231.2010.02255.x
8.
PlanasR, BallestéB, AlvarezMA, et al.Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol, 2004; 40(5):823–830; doi: 10.1016/j.jhep.2004.01.005
9.
ZipprichA, Garcia-TsaoG, RogowskiS, et al.Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int, 2012; 32(9):1407–1414; doi: 10.1111/j.1478-3231.2012.02830.x
10.
Vieira SilvaS, FreireE, Pessegueiro MirandaH. Palliative care in end-stage liver disease patients awaiting liver transplantation: Review. GE Port J Gastroenterol, 2020; 27(6):417–428; doi: 10.1159/000507336
11.
FoxE, Landrum-McNiffK, ZhongZ, et al.Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. JAMA, 1999; 282(17):1638–1645; doi: 10.1001/jama.282.17.1638
12.
ChristakisNA, LamontEB. Extent and determinants of error in doctors' prognoses in terminally ill patients: Prospective cohort study. BMJ, 2000; 320(7233):469–472; doi: 10.1136/bmj.320.7233.469
13.
HawleyP. Barriers to access to palliative care. Palliat Care, 2017; 10:1178224216688887; doi: 10.1177/1178224216688887
14.
VermaM, TapperEB, SingalAG, et al.Nonhospice palliative care within the treatment of end-stage liver disease. Hepatology, 2020; 71(6):2149–2159; doi: 10.1002/hep.31226
15.
PatelAA, WallingAM, Ricks-OddieJ, et al.Palliative care and health care utilization for patients with end-stage liver disease at the end of life. Clin Gastroenterol Hepatol, 2017; 15(10):1612–1619.e4; doi: 10.1016/j.cgh.2017.01.030
16.
HCUP Databases. Healthcare Cost and Utilization Project (HCUP). 2016–2020. Agency for Healthcare Research and Quality, Rockville, MD. Available from: www.hcup-us.ahrq.gov/databases.jsp [Last accessed: July 2023].
17.
SohalA, ChaudhryH, DhaliwalA, et al.Gender differences in esophageal variceal bleeding in the United States. Ann Med, 2022; 54(1):2115–2122; doi: 10.1080/07853890.2022.2104920
18.
SohalA, ChaudhryH, SinglaP, et al.The burden of Clostridioides difficile on COVID-19 hospitalizations in the USA. J Gastroenterol Hepatol, 2023; In Press; doi: 10.1111/jgh.16128
19.
SohalA, ChaudhryH, KohliI, et al.Hospital frailty risk score predicts worse outcomes in patients with chronic pancreatitis. Ann Gastroenterol, 2023; 36(1):73–80; doi: 10.20524/aog.2022.0765
20.
MenendezME, NeuhausV, van DijkCN, et al.The Elixhauser comorbidity method outperforms the Charlson index in predicting inpatient death after orthopaedic surgery. Clin Orthop Relat Res, 2014; 472(9):2878–2886; doi: 10.1007/s11999-014-3686-7
21.
World Health Organization. Strengthening of palliative care as a component of integrated treatment throughout the life course. J Pain Palliat Care Pharmacother, 2014; 28(2):130–134; doi: 10.3109/15360288.2014.911801
22.
TavaresP, RodriguesC, NetoIG. The impact of COVID-19 on palliative care: Perspective of healthcare professionals. Cureus, 2021; 13(11):e19522; doi: 10.7759/cureus.19522
23.
BarnesA, WoodmanRJ, KleinigP, et al.Hepatobiliary and pancreatic: Early palliative care referral in patients with end-stage liver disease is associated with reduced resource utilization. J Gastroenterol Hepatol, 2020; 35:840–845; doi: 10.1111/jgh.14877
24.
HwangJ, ShenJ, KimS, et al.Ten-year Trends of utilization of palliative care services and life-sustaining treatments and hospital costs associated with patients with terminally ill lung cancer in the United States from 2005 to 2014. Am J Hosp Palliat Care, 2019; 12(36):1105–1113; doi: 10.1177/1049909119852082
25.
HugarL, LopaS, YabesJ, et al.Palliative care use amongst patients with bladder cancer. BJU Int, 2019; 6(123):968–975; doi: 10.1111/bju.14708
26.
WilkieD, HongY, TurnerK, et al.Utilization pattern and service settings of palliative care for patients with metastatic non–small cell lung cancer. Cancer, 2019; 24(125):4481–4489; doi: 10.1002/cncr.32478
27.
MaetensA, DeliensL, Van den BlockL, et al.Are we evolving toward greater and earlier use of palliative home care support? A trend analysis using population-level data from 2010 to 2015. J Pain Symptom Manage, 2019; 58(1):19–28.e10; doi: 10.1016/j.jpainsymman.2019.04.008
28.
UfereNN, DonlanJ, WaldmanL, et al.Barriers to use of palliative care and advance care planning discussions for patients with end-stage liver disease. Clin Gastroenterol Hepatol, 2019; 17(12):2592–2599; doi: 10.1016/j.cgh.2019.03.022
29.
LangbergKM, KapoJM, TaddeiTH. Palliative care in decompensated cirrhosis: A review. Liver Int, 2018; 38(5):768–775; doi: 10.1111/liv.13620
30.
JohnsonKS. Racial and ethnic disparities in palliative care. J Palliat Med, 2013; 16(11):1329–1334; doi: 10.1089/jpm.2013.9468
31.
GriggsJJ. Disparities in palliative care in patients with cancer. J Clin Oncol, 2020; 38(9):974–979; doi: 10.1200/JCO.19.02108
32.
GardnerDS, DohertyM, BatesG, et al.Racial and ethnic disparities in palliative care: A systematic scoping review. Fam Soc, 2018; 99(4):301–316; doi: 10.1177/1044389418809083
33.
RushB, WalleyKR, CeliLA, et al.Palliative care access for hospitalized patients with end-stage liver disease across the United States. Hepatology, 2017; 66(5):1585–1591; doi: 10.1002/hep.29297
34.
KathpaliaP, SmithA, LaiJC. Underutilization of palliative care services in the liver transplant population. World J Transplant, 2016; 6(3):594–598; doi: 10.5500/wjt.v6.i3.594
35.
JohnsonKS, Elbert-AvilaKI, TulskyJA. The influence of spiritual beliefs and practices on the treatment preferences of African Americans: A review of the literature. J Am Geriatr Soc, 2005; 53:711–719; doi: 10.1111/j.1532-5415.2005.53224.x
36.
RizzutoJ, AldridgeMD. Racial disparities in hospice outcomes: A race or hospice-level effect?. J Am Geriatr Soc, 2018; 66(2):407–413; doi: 10.1111/jgs.15228
37.
OrnsteinKA, RothDL, HuangJ, et al.Evaluation of racial disparities in hospice use and end-of-life treatment intensity in the REGARDS Cohort. JAMA Netw Open, 2020; 3(8):e2014639; doi: 10.1001/jamanetworkopen.2020.14639
38.
JohnsonT, WaltonSJr, LevineS, et al.Racial and ethnic disparity in palliative care and hospice use. Am J Manag Care, 2020; 26(2):e36–e40; doi: 10.37765/ajmc.2020.42399
39.
DaviesJM, SleemanKE, LenizJ, et al.Socioeconomic position and use of healthcare in the last year of life: A systematic review and meta-analysis [published correction appears in PLoS Med 2019 Jul 18;16(7):e1002878]. PLoS Med, 2019; 16(4):e1002782; doi: 10.1371/journal.pmed.1002782
40.
BowersSP, ChinM, O'RiordanM, et al.The end of life experiences of people living with socio-economic deprivation in the developed world: An integrative review. BMC Palliat Care, 2022; 21(1):193; doi: 10.1186/s12904-022-01080-6
41.
WalesJ, KaliaS, MoineddinR, et al.The impact of socioeconomic status on place of death among patients receiving home palliative care in Toronto, Canada: A retrospective cohort study. J Palliat Care, 2020; 35(3):167–173; doi: 10.1177/0825859719855020
42.
DaviesJM, MaddocksM, ChuaKC, et al.Socioeconomic position and use of hospital-based care towards the end of life: A mediation analysis using the English Longitudinal Study of Ageing. Lancet Public Health, 2021; 6(3):e155–e163; doi: 10.1016/S2468-2667(20)30292-9
43.
QureshiD, TanuseputroP, PerezR, et al.Early initiation of palliative care is associated with reduced late-life acute-hospital use: A population-based retrospective cohort study. Palliat Med, 2019; 33(2):150–159; doi: 10.1177/0269216318815794
44.
SaeedF, HoergerM, NortonSA, et al.Preference for palliative care in cancer patients: Are men and women alike?. J Pain Symptom Manage, 2018; 56(1):1–6.e1; doi: 10.1016/j.jpainsymman.2018.03.014
45.
TrubyLK, O'ConnorC, FiuzatM, et al.Sex differences in quality of life and clinical outcomes in patients with advanced heart failure: Insights from the PAL-HF trial. Circ Heart Fail, 2020; 13(4):e006134; doi: 10.1161/CIRCHEARTFAILURE.119.006134
46.
JustE, CasarettDJ, AschDA, et al.Differences in terminal hospitalization care between U.S. men and women. J Pain Symptom Manage, 2016; 52(2):205–211; doi: 10.1016/j.jpainsymman.2016.01.013
47.
FletcherK, PrigersonHG, PaulkE, et al.Gender differences in the evolution of illness understanding among patients with advanced cancer. J Support Oncol, 2013; 11:126–132. doi: 10.12788/j.suponc.0007.
48.
SkulasonB, HauksdottirA, AhcicK, et al.Death talk: Gender differences in talking about one's own impending death. BMC Palliat Care, 2014; 13(1):8; doi: 10.1186/1472-684X-13-8
49.
UllrichA, GrubeK, HlawatschC, et al.Exploring the gender dimension of problems and needs of patients receiving specialist palliative care in a German palliative care unit—The perspectives of patients and healthcare professionals. BMC Palliat Care, 2019; 18(1):59; doi: 10.1186/s12904-019-0440-7
50.
MediciV, RossaroL, WegelinJA, et al.The utility of the model for end-stage liver disease score: A reliable guide for liver transplant candidacy and, for select patients, simultaneous hospice referral. Liver Transpl, 2008; 14(8):1100–1106; doi: 10.1002/lt.21398
51.
VermaM, BakitasMA. Creating effective models for delivering palliative care in advanced liver disease. Curr Hepatol Rep, 2021; 20(2):43–52; doi: 10.1007/s11901-021-00562-0
52.
VermaM, KosinskiAS, VolkML, et al.Introducing palliative care within the treatment of end-stage liver disease: The study protocol of a cluster randomized controlled trial. J Palliat Med, 2019; 22(S1):34–43; doi: 10.1089/jpm.2019.0121
53.
DeNofrioJC, VermaM, KosinskiAS, et al.Palliative care always: Hepatology-Virtual Primary Palliative Care Training for Hepatologists. Hepatol Commun, 2022; 6(4):920–930; doi: 10.1002/hep4.1849
54.
GuptaK, HansB, KhanA, et al.A retrospective study on use of palliative care for patients with alcohol related end stage liver disease in United States. World J Hepatol, 2022; 14(9):1817–1829; doi: 10.4254/wjh.v14.i9.1817
55.
BackAL, LiYF, SalesAE. Impact of palliative care case management on resource use by patients dying of cancer at a Veterans Affairs medical center. J Palliat Med, 2005; 8(1):26–35; doi: 10.1089/jpm.2005.8.26
56.
GadeG, VenohrI, ConnerD, et al.Impact of an inpatient palliative care team: A randomized control trial. J Palliat Med, 2008; 11(2):180–190; doi: 10.1089/jpm.2007.0055
57.
BarnesA, WoodmanRJ, KleinigP, et al.Early palliative care referral in patients with end stage liver disease is associated with reduced resource utilisation. J Gastroenterol Hepatol, 2019; In Press; doi: 10.1111/jgh.14877
58.
ThongprayoonC, KaewputW, PetnakT, et al.Impact of palliative care services on treatment and resource utilization for Hepatorenal Syndrome in the United States. Medicines (Basel), 2021; 8(5):21; doi: 10.3390/medicines8050021
59.
HudsonBE, AmeneshoaK, GopfertA, et al.Integration of palliative and supportive care in the management of advanced liver disease: Development and evaluation of a prognostic screening tool and supportive care intervention. Frontline Gastroenterol, 2017; 8(1):45–52; doi: 10.1136/flgastro-2016-100734
60.
ReVL, III, LimJK, GoetzMB, et al..Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the veterans aging cohort study. Pharmacoepidemiol Drug Saf, 2011; 20(7):689–699.
61.
HoVP, BenskenWP, KoroukianSM. Palliative care and aggressive interventions after falling: A Nationwide Inpatient Sample analysis. Palliat Support Care, 2022; 20(1):101–106; doi: 10.1017/S1478951521000158
62.
MojtahediZ, YooJW, CallahanK, et al.Inpatient palliative care is less utilized in rare, fatal extrahepatic cholangiocarcinoma: A Ten-Year National Perspective. Int J Environ Res Public Health, 2021; 18(19):10004; doi: 10.3390/ijerph181910004
63.
Nwogu-OnyemkpaE, DongarwarD, SalihuHM, et al.Inpatient palliative care use by patients with sickle cell disease: A retrospective cross-sectional study. BMJ Open, 2022; 12(8):e057361; doi: 10.1136/bmjopen-2021-057361
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
